Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00308100
Other study ID # BFP502
Secondary ID
Status Terminated
Phase Phase 4
First received March 28, 2006
Last updated January 14, 2009
Start date October 2005
Est. completion date July 2008

Study information

Verified date January 2009
Source Fresenius Kabi
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

There are no standardized plasma volume replacement protocols during liver transplantation surgery. The current study is designed to compare efficacy, safety, and costs of perioperative volume replacement with Voluven (Hydroxyethyl starch 130/0.4) and albumin in patients undergoing liver transplantation.


Description:

End-stage liver disease is one of the major diseases leading to death. With advancement of transplantation surgery and perioperative anesthesia management, liver transplantation has become an effective method to recover patients' liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance, such as blood coagulation dysfunction, electrolyte disequilibrium, hypoalbuminaemia, low hematocrit, low hemoglobin and acid-base imbalance etc. exist in end stage cirrhosis patients with liver transplantation. Such abnormalities in the internal milieu could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult.

Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. At the same time, the level of albumin concentration is also used as an important criterion of prognosis. When the level of albumin concentration in serum is below 35 g/L, postoperative mortality rates and complications will increase significantly. In fact, it has been the focus of debate for many years whether albumin should be used for volume replacement in critically ill patients. Boldt and his colleagues demonstrated that albumin has little positive influence on the prognosis of critically ill patients. However, Shwe deemed albumin beneficial to critically ill patients. Simon suggested that albumin is given mainly for treating hypovolemia instead of increasing the level of albumin concentration in serum. However, at the same time, he admitted there is no advantages of albumin in comparison to other colloid solutions and, furthermore, it is more expensive.

Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function.

The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.


Recruitment information / eligibility

Status Terminated
Enrollment 53
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Aged 18-65 years, male or female

- Elective liver transplantation

- United Network for Organ Sharing (UNOS) Level 2A/B or 3

- Serum albumin = 30 g/L

- Comprehend all the procedures of this study

- Willing and able to give informed consent

Exclusion Criteria:

- Uncontrolled exo-hepatic malignant carcinomas

- Uncontrollable infections (including HIV infection)

- Need support of artificial liver or kidney, ventilator-dependant, coma or unstable hemodynamically

- Patients with a history of hypersensitivity to hydroxyethyl starch or albumin

- Urinary output less than 500 ml within 24 hours after operation

- Patients with intracranial bleeding

- Patients with other colloids for treating hypovolemia

- Patients with pulmonary edema

- Pregnant women or females of childbearing potential and lactating mothers

- Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxyethylstarch 130/0.4
HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
5% Albumin
5% albumin, administered intra- and perioperatively

Locations

Country Name City State
China People's Hospital of Peking University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Fresenius Kabi

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemodynamics From pre-operative period till discharged from hospital No
Secondary Child-Turcotte-Pugh (CTP) score From pre-operative period till discharged from hospital No
Secondary Model for End-Stage Liver Disease (MELD) score From pre-operative period till discharged from hospital No
See also
  Status Clinical Trial Phase
Completed NCT04519203 - The Use of Surgical Pleth Index in Guiding Anesthesia in Gastroenterological Surgery N/A
Completed NCT02296619 - The Effects of Transversus Abdominis Plane Block in Patients Undergoing Total Abdominal Hysterectomy Phase 4
Completed NCT02043132 - Tranexamic Acid in Reverse Total Shoulder Arthroplasty Phase 2/Phase 3
Withdrawn NCT00861367 - Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate N/A
Completed NCT04517461 - Coagulation and Vitamin K in Head and Neck Microvascular Free Flap Surgery
Completed NCT02419053 - Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children N/A
Active, not recruiting NCT04443465 - Patient Experiences of IONM and Outcomes
Recruiting NCT06426381 - The Effect of Therapeutic Touch Applied During Knee Replacement Surgery on Anxiety, Vital Signs and Comfort Level N/A
Completed NCT05550181 - Intraoperative Hypocapnia in PROVHILO and PROBESE
Completed NCT01664806 - Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin Phase 3
Completed NCT00683293 - Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy N/A
Terminated NCT00364494 - Hemodilution and Outcome in Cardiac Surgery N/A
Completed NCT05136157 - Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control Early Phase 1
Terminated NCT03665259 - Lower Inspiratory Oxygen Fraction for Preoxygenation N/A
Completed NCT02773199 - Effects of Preoperative Fasting on ECG and Vital Parameters N/A
Completed NCT03974321 - Intraoperative Hypotension and Perioperative Myocardial Injury
Completed NCT00197353 - Study of Different Concentrations of Epidural Bupivacaine for the Effects on Vasodilatation and Sensory Block Phase 3
Enrolling by invitation NCT05270603 - The Intraoperative Complication Assessment and Reporting With Universal Standards - Calculator (ICARUS-C)
Completed NCT03467230 - Performance Assessment of the PMD-200 Under General Anesthesia
Recruiting NCT05276167 - Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma N/A